Literature DB >> 20702190

An in vitro method for estimating ocular irritation.

R J Soto1, V C Gordon.   

Abstract

Three variations of an in vitro assay system called EYTEX were evaluated by comparing maximum in vivo Draize scores for 70 experimental consumer product formulations. The EYTEX in vitro assay (EIA) was chosen for in-house evaluation because it is an economical, objective system that is easy to learn. In the present study, double-blind samples were tested at National Testing Corporation (Lab 1) and an in-house laboratory (Lab 2). All products were tested in the standard, membrane, and rapid membrane (RMA) EIA. Most samples qualified for the membrane and RMA EIA, whereas approximately half qualified for the standard EIA. Results from both Labs 1 and 2 were highly correlated. The RMA assay gave the best overall performance of the three assays. The RMA EIA demonstrated the best correlation with in vivo data and qualified the highest percentage of formulations. RMA showed a 7.5% false positive identification of irritants. False negatives or irritants not identified were 6.1%. The predictive value for identifying irritants was 89%. Specificity or the ratio of non-irritants giving negative results to the total was 84%. The ratio of positive irritants to the total or sensitivity was 93%. Based on these results, EIA has demonstrated value as a screening tool for a broad variety of consumer products. Advantages of EIA include the opportunity to test undiluted products, reduce animal use, and lower costs.

Entities:  

Year:  1990        PMID: 20702190     DOI: 10.1016/0887-2333(90)90076-6

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  1 in total

1.  Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery.

Authors:  Estefanía Vega; M Antònia Egea; Ana Cristina Calpena; Marta Espina; M Luisa García
Journal:  Int J Nanomedicine       Date:  2012-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.